Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
Global Partners LP(US:GLP) Prnewswire·2025-09-17 07:30The Phase Ib MAD study is a randomized, double-blind, placebo-controlled study, conducted in the U.S., to evaluate safety and tolerability, various titration schemes, pharmacokinetics (PK) and preliminary efficacy of ASC30 once-daily oral tablet in participants with obesity (body mass index (BMI): 30-40 kg/m). Â ASC30 once-daily oral tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment in MAD cohort 2 (weekly titrations of 2 mg, 10 mg, 20 mg, and 40 mg) ...